

## Cardiac Dysrhythmias

Two types of cardiac tissues.

### Myocardial Muscle.

(atrial & ventricular) \_\_\_\_\_ responsible for pumping action of heart.

### Specialized Conducting Tissue.

1-IMPULSE INITIATION

2-IMPULSE CONDUCTION


SA node (sinoatrial node),

AV node (atrioventricular), &

His – Purkinje System



## Normal Conduction



- The impulse is initiated at the SA node and spreads from right to left atrium
- Slowing of conduction occurs at the AV node
- The right and left ventricle are simultaneously activated via the His Purkinje system

Scotpi  
to beam  
follow  
I've



### SA Node.

Impulse spontaneously formed----- Automatiaty.  
Highest frequency of spontaneous discharge, 70  
times / minute \_\_\_\_\_ so control the heart .

It is a pacemaker.

### AV Node.

If SA node fails to function, next part that takes  
over the function is AV node \_\_\_\_\_ 45  
discharges / minute.


### A Site in His - Purkinje System.

Frequency 25 discharge / min.


RECORDING OF  
IMPULSE GENERATION  
& CONDUCTION



SA node generates impulse;  
atrial excitation begins



Impulse delayed  
at AV node



AV node



Impulse passes to  
heart apex; ventricular  
excitation begins



Bundle  
branches



Ventricular excitation  
complete



Purkinje  
fibers





# Arrhythmias or Dysrhythmias

(Defect of Heart Rate & Rhythm)

Altered **rate** of automatic discharge

or

Abnormality of the **mechanism** by which **Impulse is generated**

or

**Abnormality in Conduction of impulses .**

or

**Both**



## Arrhythmias or Dysrhythmias

(Defect of Heart Rate & Rhythm)

Altered **rate** of automatic discharge

or

Abnormality of the **mechanism** by which **Impulse is generated**

or

**Abnormality in Conduction of impulses .**

or

**Both**






## Cardiac Dys or Arrhythmias.

Two types

1. Atrial arrhythmias
2. Ventricular arrhythmias

### Atrial Arrhythmias

1. Arrhythmias of SA node Origin.
  2. Atrial Pre mature or Extrasystole
  3. Atrial Tachycardia
  4. Atrial Flutter
  5. Atrial Fibrillation
- 



## 1. Arrhythmias of SA node Origin.

a) Sinus Bradycardia.      b) Sinus tachycardia

c) sinus Arrhythmias

### A) Sinus Bradycardia

Heart rate below 60 / min, may be as low as 35, but usually between 45 – 50 / min

1) Normally common in athletes & physically trained people.

2) Also manifests when ↑ vagal tone e.g vomiting, fainting, vasovagal attack.

3) T/M with parasympathomimetics or sympatholytics (propranolol) hypothermia, Dec.pressure


## b. Sinus Tachycardia.

Sinus initiated heart rate above 100 / min  
\_\_\_\_\_ not exceed 160 / min in adults \_\_\_\_\_

**With carotid massage.**

↓ slowly but gradually

**May be seen in**

1. Hereditary, during physical & mental stress.
  2. Psychogenic
  3. Hypotension, acute hemorrhage, chronic anemia, pulmonary embolism, & in fever.
- 



4. Acute rheumatic fever & pericarditis
5. Organic heart disease \_\_\_\_\_ sinus tachycardia \_\_\_\_\_ early sign of heart failure.

c. Sinus Arrhythmias.

Common in children & youth.

Pulse rate slow & irregular rhythm.

2. Atrial Premature Beats or Extrasystoles.

The beats occur prematurely.



An **ectopic focus** develop in some portion of atria which discharge intermittently at variable intervals producing premature beats.

**Re-entry** mechanism may also responsible for this condition.

## 2. Atrial Tachycardia.

Atrial heart rate **above** 100 / min.

ECG shows **three or more** consecutive atrial premature beats.





### 3. Atrial Flutter.

Due to abnormal focus or group of foci atria beat very **rapidly** but **regular** rate.

**ECG** \_\_\_\_ Continuous regular activity that occur at a rate of **250 to 350** per minute .

The P wave \_\_\_\_ **identical** in spacing, size & contour, showing **saw teeth** appearance.

#### 4. Atrial Fibrillation.

Due to **rapid irregular** heart action, **no coordination** between atrial muscle fibers, some muscle fibers contract while other relax.

The **contraction** is quite **incomplete** i.e. fibers only **fibrillate**.

Thus **atria** are only ineffective

e.g mitral stenosis, hyperthyroidism, ischemic heart disease, digitalis toxicity.

ECG \_\_\_\_ **absence** of "P" wave.





“F” waves occur usually at rates of 300 to 600 per minute and vary in amplitude and contour.

**AV block results** in the ventricles beating at a slower rate than atria.

**Ventricular beats** are weak, so they fail to produce pulse in the arteries.

**Heart rate taken** by feeling an artery will be less than that by listening over heart.

This is **called Pulse Deficit**.



In this resting state \_\_\_\_\_ **interior of the cell is negative** with respect to the exterior(+ ve) due to deposition of ions ( $\text{Na}^+$ ,  $\text{K}^+$ , and  $\text{Ca}^{++}$ ) across its membrane i.e. it is polarized.

**Polarized**

+++++ Outside



----- Inside






**Physiological Aspect of Formation  
& propagation of Elec. Impulses  
(Ionic Movements Into & Out of  
Cardiac Cells)**

All cells in the body show a  
**difference** in electrical voltage  
between their interior & exterior  
\_\_\_\_\_ **membrane potential.**


VGA



1024 x 768 60Hz


**Phase "O"** is a rapid depolarization of the cell membrane that is associated with a fast inflow of sodium ion through channels that are selectively permeable to these ions.

**Phase 1** is a short initial period of rapid repolarization brought about mainly by an outflow of potassium ions.





When ionic changes occur \_\_\_\_\_ a rapid **redistribution of ions** \_\_\_\_\_ potential alters to positive inside (depolarization).



Then subsequent and flows of ions restore the resting potential (repolarization).

These ionic movements may be separated into **phases in cardiac AP**



**Phase 2** is a period where there is a **delay in repolarization** caused by mainly a slow movement of **Ca<sup>++</sup> ions** from the exterior into the cells through the channel that are selectively permeable to these ions.

**Phase 3** is a second period of rapid repolarization during which **K<sup>+</sup> ions** move out of the cell.





# PHASES OF MYOCARDIAL ACTION POTENTIAL

## Phase 0

Depolarization; (Inflow of  $\text{Na}^+$ )

## Phase 1

Early Repolarization; (rapid outflow of  $\text{K}^+$ )

## Phase 2


Plateau phase; (Inflow of  $\text{Ca}^{++}$ )

## Phase 3

Rapid Repolarization; ( $\text{K}^+$  outflow)


## Phase 4 ( automaticity ):

( $\text{Na}^+$  outflow,  $\text{K}^+$  inflow,  $\text{Ca}^{++}$  outflow)



## VAUGHAN WILLIAMS CLASSIFICATION OF ANTI-ARRHYTHMIC DRUGS

- **Class I:** block sodium channels
  - Ia (quinidine,)  $\uparrow$ AP
  - Ib (lignocaine)  $\downarrow$ AP
  - Ic (flecainide)  $\leftrightarrow$ AP
- **Class II**  $\beta$ -adrenoceptor antagonists (atenolol, sotalol)
- **Class III:** prolong action potential and prolong refractory period (suppress re-entrant rhythms) (amiodarone, sotalol)
- **Class IV:** Calcium channel antagonists. Impair impulse propagation in nodal and damaged areas (verapamil)






## Classification of Drugs & Mode of Action

Therapeutically useful channel blocking drugs have a **high affinity for activated channels** (i.e. during phase 0) or inactivated channels i.e. during phase 2, but low affinity for rested channels.

### Class 1 Na<sup>+</sup> Channel Blockade.

These drugs **restrict the rapid inflow** of sodium during phase "0".





### **In phase 1 & 2**

The cell is absolutely **refractory state** and is **incapable** of responding further to any stimulus,

### **In phase 3**

The relative refractory period, the cell may depolarize if the stimulus is strong enough.





## **Aims of the therapy of arrhythmias**

- To reduce sympathetic parasympathetic activity*
- and modify conduction*
- in the myocardium to secondary arrhythmias by*  
*avoiding electrical remodeling.*

**The major mechanisms to accomplish these goals are**

- 1. Sodium Channel Blockers**
- 2. Blockade of Sympathetic Autonomic Effects in the Heart**
- 3. Prolongation of Effective Refractory Period**





**Phase 4 is fully repolarized state** during which  $K^+$  ions move back into and  $Na^+$  &  $Ca^{++}$  move out of the cell.

During this phase, the **interior** of the cells become gradually **less negative** until a potential is reached which allows the rapid repolarization (Phase 0) to occur and the cycle is repeated.





## Characteristics of Antiarrhythmic Drugs

1. Antiarrhythmic drugs **decrease** the automaticities of ectopic pace maker more than that of the SA node.
2. They also **reduce** conduction and excitability.
3. They **increase the refractory period** to a greater extent in depolarized tissue than in normal polarized tissue.





**USES** Effective only in ventricular dys-rhythmias.

### Class 1 C.

e.g. Flecainide, Propafenone,

- They act by **blocking the Na<sup>+</sup> channel**
- They have negligible effect or no effect on action potential and refractoriness & dissociate from the channel with slow kinetics

**USES** - Effective for supra ventricular and ventricular dysrhythmias

### Class II.

e.g. Sympatholytic especially,  $\beta$ -blockers,

Drugs include those that **reduce adrenergic activity in the heart,**



& thus slow the maximum rate of depolarization.

Another term for this property is **membrane stabilizing activity**", because they have local anesthetic effect as well.

Class 1 (Na<sup>+</sup> Channel Blockers) ARE

Sub divided Class 1A, 1B & 1C

Due to the reasons-----they differ from kinetic properties although the basic mechanism is the same (Na<sup>+</sup> channel blocked)

SO

Sub classification reflects on APD (action potential Duration) & kinetics of Na<sup>+</sup> channel



### Class 1 A.

e.g. Quinidine, procainamide, disopyramide

- They block the  $\text{Na}^+$  channel.
- These drugs **lengthen action potential** duration (APD), refractoriness & dissociate from the channel with intermediate kinetics

**USES..** Effective for supra ventricular & ventricular dysrhythmias.

### Class 1 B.

e.g. lignocaine, mexiletine, phenytoin etc.

- They block the  $\text{Na}^+$  channel.
- The drugs **shorten action potential** duration and refractoriness & dissociate from the channel with rapid kinetics-

How Antiarrhythmic Effect is produced (As APD dec.)

- Though APD decreased but this increases diastole & Extends the time for recovery



i.e. they **reduce** the **sympathetic tone** in the heart, reduce automatic discharge (phase 4) and protect against adrenergically stimulated ectopic pacemaker.

### Class III.

— e.g. Amiodarone, Bretylium

— Drugs that **prolong effective refractory period** by prolonging action potential (no effect on sodium inflow in phase 0).

Prolongation of cellular refractoriness (phase 1, 2, & 3)

**beyond a critical** point may prevent a reentry circuit being completed.

**Class V ( Miscellaneous ):**

Adenosine

Magnesium sulphate

Digoxin

Ranolazine

Atropine

2. Catheter Ablation:


3. Implantable Cardioversion Defibrillator  
( ICD ):



as it has antimuscarinic action which will **enhance AV conduction** and heart rate may increase.


### Toxicity.

#### Cardiac.

a. Due to antimuscarinic effect in heart, vagal effects are inhibited \_\_\_\_\_ **sinus rate** and atrioventricular conduction. 

So it should not be given alone.

Give a drug which **slows atrioventricular conduction** e.g. a  $\text{Ca}^{++}$  blocker or  $\beta$ -blocker or digitalis then give quinidine.




**Quinidine Syncope** \_\_\_ 1-5 %

characterized recurrent light headedness and episodes of fainting.

These symptoms are a result of torsade de pointes i.e. **serious ventricular dysrhythmias** associated with electrocardiographic QT prolongation.

Extra Cardiac Effects.

1. GIT \_\_\_ diarrhea, nausea, vomiting \_\_\_  
1/3 or half of the patients.
  2. Cinchonism \_\_\_ headache, dizziness, tinnitus
- 



3. Rarely rashes, angioneurotic edema, fever, hepatitis & thrombocytopenia.

4. Can ↑ digoxin plasma levels and precipitate digitalis toxicity in patients taking digoxin.

### Pharmacokinetics.

**Given orally**, rapidly absorbs from GIT.

80 % bound to plasma proteins.

**Metabolized** in liver \_\_\_\_\_ 20 % excreted unchanged in urine.

**Half life** is 6 hours.



## Procainamide



Half life \_\_\_\_\_ 3 hrs.

### Cardiac Effects.

Similar to quinidine.

Somewhat less effective in suppressing abnormal ectopic pacemaker activity, but more effective in blocking  $Na^+$  channel in depolarized cells.

### Extra Cardiac Effects.

Ganglion blocking properties \_\_\_\_\_   
peripheral vascular resistance \_\_\_\_\_   
hypotension, especially with I/V use.



## Toxicity.

### Cardiac.

Same as quinidine \_\_\_\_ hypotension, cardiac failure (-ve inotropic effect occur and dysrhythmias may be included e.g. torsade de pointes)

### Extra Cardiac.

1. In long term use (in 80% patients) \_\_\_\_ develop abnormal **antinuclear (ANA) factor titers** in the blood 30 % proceed to systemic lupus erythematosus like syndrome \_\_\_\_ consisting of arthralgia

and arthritis.

These symptoms are **dose related** and is more common in **slow accetylators** and usually regress when drug is withdrawn.

2. Some patients \_\_\_\_\_ pleuritis, pericarditis, parenchymal pulmonary disease.

Other effects include nausea, diarrhea, rash, hepatitis, & agranulocytosis (approximately 0.2 %)






SLE less common in these patients.  
Procainamide is eliminated by hepatic metabolism to NAPA and by renal elimination.

### Dose.

If a rapid procainamide effect \_\_\_\_\_ I/V  
loading dose up to 12 mg/kg at a rate of  
0.3 mg/kg/min \_\_\_\_\_ followed by  
maintenance dose \_\_\_\_\_ 2.5 mg/min.

### Uses.

1. Used in atrial and ventricular arrhythmias.
- 

## Pharmacokinetics.


Safely can be given I / V or I / M.

Well absorbed **orally**.

Major metabolite is **N-acetylprocainamide**  
(NAPA).

↑ accumulation \_\_\_\_\_ torsade de pointes  
during therapy, especially in patients  
with renal failure.

Some patients **rapidly acetylate**  
procainamide and develop high levels of  
NAPA.






2. It is a drug of **second choice** after lidocaine for the treatment of sustained ventricular arrhythmias associated with acute myocardial infarction.

### Disopyramide

Effects similar to those of quinidine but **antimuscarinic actions** are more than quinidine.

About **50 %** of the dose is **eliminated in the urine** by glomerular filtration and the remainder is metabolized.



## Toxicity.

### Cardiac.

- Same as quinidine.
- In addition, disopyramide possesses negative inotropic effects, more dangerous in patients with left ventricular failure.
- So **should not be** used in patients with congestive cardiac failure.

### Extra Cardiac.

Antimuscarinic, effects (atropine-like)





## Toxicity.

### Cardiac.

- Same as quinidine.
- In addition, disopyramide possesses negative inotropic effects, more dangerous in patients with left ventricular failure.
- So **should not be** used in patients with congestive cardiac failure.

### Extra Cardiac.

Antimuscarinic, effects (atropine-like)



Toxicity.

Cardiac.

Least cardiotoxic.

Some times can **exacerbate ventricular arrhythmias** in less than 10 % of patients.

In 1 % of patents with acute myocardial infarction, lidocaine patients should stand still.

**In large doses** \_\_\_ patients with congestive cardiac failure \_\_\_ hypotension.

